Category: Uncategorized

Silly Conspiracy Theories — From Bitter Old Scott Johnson, This Morning.

~ condor ~ Leave a comment

Scott thinks he should be able to say whether former two term Presidents… are allowed inside the Beltway, to meet with fellow party members.

Geez, Scott — this is not the old USSR Politburo, or the current state party councils in China run by Xi… where ex-leaders are grabbed and run out of town, or disappeared to a gulag, altogether with their families.

This is just more “crazy ish“, from old pop-pop.

And consider the hypocrisy, here: whereas… Tangerine almost violently refused to leave town, and surrender the keys to 1600 Penn. — then he continually and falsely said that Mr. Biden was not even the duly elected President — for four long years, now. To this very morning. That is a threat to the system of ordered liberty, ongoing through January 2025.

Trump was (and is) defying the legitimate — and peaceful — transfer of leadership… of our nation.

So, saying that smart people do… still willingly listen to Barack H. Obama (44th) on numerous important matters… is no surprise. It is laudatory.

Do sit down, Scottie — or take some more… of your Ketamine.

Lilly’s Q3 2024 Lobby Spend [3 of 3]: Right In The Middle Of “The Majors” Pack — Election ’24 Quarter, Vs. ’23…

~ condor ~ Leave a comment

Eli Lilly certainly will face some issues upon which it must lobby once the new Congress is seated. Chief among those will be trying to blunt the inroads compounders are making — toward essentially achieving an early “generic-ification” of the semiglutide weight loss franchise drugs.

So far, the company has been moderately successful with using litigation (and/or the threat of it) to scare off the less-reputable compounders — but several FDA authorized ones remain on the field, slightly eating away at market share, and the retail price levels. But not a huge deal, as to Lilly’s stock price on the NYSE, as it still is the runaway leader in the class in the USA.

And welp, that wraps this series up for me.

[As Abbott / Baxter were not big spenders, I’ll simply say that they spent on almost all the same issues they spent on in Q2 2024, just at a slightly decreased rate.]

…Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil….

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the “Inflation Reduction Act” (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care….

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the “Inflation Reduction Act” (HR.5376); CMS National Coverage Determination on Alzheimer’s disease; The INSULIN Act….

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality; Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping….

Pharmaceutical intellectual property issues. . . .

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act….

Onward, for a cool, breezy bike ride, along the lake, now… smile.

नमस्ते

Part Two — Of Three: Merck’s Q3 2024 Lobby Spend Details, Compared To About The Same Spend In Q3 2023…

~ condor ~ Leave a comment

I think my main observation here is that Merck’s spending stayed fairly steady — while Pfizer’s essentially… fell off a cliff.

I do think Rahway is playing the longer game, hoping to blunt the required federal agency price negotiations — a promise Tangerine hinted at in 2017 (as a populist measure), and never delivered — but one Biden/Harris achieved. Will Tangerine now undo it? Who knows? I suspect he’s not even organized enough to make it a “anti-deep-state” talking point… let alone get it undone.

In any event, here’s all that from late October 2024 LDA filings (at the Senate’s public reference window):

…H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021; H.R. 830, Help Ensure Lower Patient (HELP) Copays Act; H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023; H.R. 2679, Pharmacy Benefits Manager Accountability Act; H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act; H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3285, Fairness for Patient Medications Act; H.R. 3633, PREVENT HPV Cancers Act of 2023; H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024; H.R. 4895, Lowering Drug Costs for American Families Act; H.R. 5376/S. 2474, Share the Savings with Seniors Act; H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 7635, The 340B PATIENTS Act of 2024; H.R. 8467, Farm, Food, and National Security Act of 2024; S. 150, Affordable Prescriptions for Patients Act of 2023; S. 1339, Pharmacy Benefit Manager Reform Act; S. 1895 (116th Congress) Lower Health Care Costs Act; S. 2333, Pandemic and All-Hazards Preparedness and Response Act; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019; S. 4229, Reducing Drug Prices for Seniors Act….

Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues….

General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues….

H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024….

Issues relating to: Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2024 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP); Medicaid Best Price Policy; Medicaid – Centers for Medicare & Medicaid Services notice of proposed rulemaking: “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program”….

Issues relating to: Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes….

Now you know — lovely Fall afternoon here — and Steve Hayward… is fully-delusional (no, Steve, Democrats are STILL not “snowflakes”).

Onward.

नमस्ते

Mirengoff Admits Tangerine… Is Incapable… Of Much Of Anything.

~ condor ~ Leave a comment

Paul at least is in possession of a more reality based view, both as to what the ‘24 election meant, and as to how little Tangerine will ever actually accomplish.

Paul’s view is nearly the opposite of Hinderaker’s — as we noted, after his customary highballs. [He thinks this is all no less historic than July 16, 1918 — in Russia, as the Romanovs are… removed. Hah!] Paul on the other hand is very skeptical than any military action will ever occur against US citizens or even asylum seekers. Though phrased in the negative, Paul’s statements broadly hint that any such order would be fount unlawful by the courts.

Moreover, this is an admission that any such order, to use the military to deport asylum seekers do not yet have paper, but do you have to process hearing rights… Would take months if not years to litigate in the courts, ultimately likely reaching the Supreme Court… Sometime in late 2026 or early 2027.

Between now, and then, I am confident that the military would not honor any such order from tangerine.

And the Head of the Joint Chiefs tonight (almost) said just that — in remarks quoted in the Washington Post. While Paul claims it is not likely to come to that, he admits there would be very little that Tangerine might do, to shorten that perhaps 3.5 year delay in any such order being executed.

And it likely never would be authorized, even by the conservative Supremes.

So I think it wise (henceforth) to ignore Hinderaker’s more manic fever dreams of an authoritarians’ / fascists’ / populists’ “revolution”.

Ain’t gonna happen, son.

Out.

Detailing The Three Remaining “Big Spenders” — On Lobbyists, In Q3 2024… [Part 1 of 3]

~ condor ~ Leave a comment

Since it was the largest in Q3, 2024 — let’s start off with Amgen… it is the most “biotech-ey” of the big spenders this quarter. And as we said in the last post, I do expect to see much higher spend levels, out of Pfizer — in the new year, when the new Congress is seated.

But for now, that company is in the “small guys‘” pack. Amgen, though — for the past four years at least, has been near the top — outspending, compared to its proportionate asset sizes / market value. This is true again, at nearly 25% more than Merck.

…Issues related to drug pricing reform; Changes to Public law 117-1769 Inflation Reduction Act; Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act; S. 113 Prescription Pricing for the People Act of 2023; S.127 Pharmacy Benefit Manager Transparency Act; H.R. 830/ S 1375 HELP Copays Act; H.R. 485 Protecting Health Care for All Patients Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 2534 PROTECT 340B Act of 2023; H.R. 3561 the PATIENT Act; S. 1542 DRUG Act; S. 1967 PBM Act; H.R. 3503 The NIH Clinical Trials Diversity Act; Issues related to cardiovascular disease awareness and treatment; Issues related to Federal Trade Commission; FDA issues; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Biosimilars reimbursement issues, no specific bill; Supply Chain Issues, no specific bill; Issues related to 340B; Issues related to pharmacy benefit managers; Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program; H.R. 4818/ S. 2407 Treat and Reduce Obesity Act; S. 2305 Biosimilar Red Tape Elimination Act; S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act; Issues related to PAHPA reauthorization; Modernizing and Ensuring PBM Accountability Act (Finance Committee); S. 652/ HR2630 SAFE Step Act; S. 2474/ HR 5376 Share the Savings with Seniors Act; S. 2456 Protecting Seniors from High Drug Costs Act; H.R. 4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program; H.R. 3281 Protecting Patients Against PBM Abuses Act; H.R. 4822 Health Care Price Transparency Act of 2023; S. 1339 Pharmacy Benefit Manager Reform Act; H.R. 2679 Pharmacy Benefits Manager Accountability Act; H.R. 4507 Transparency in Coverage Act of 2023; H.R. 1352 Increasing Access to Biosimilars Act of 2023; H.R. 2880 Protecting Patients Against PBM Abuses Act; Issues pertaining to the implementation of PL 97-414 “Orphan Drug Act,” all provisions; H.R. 5539 Orphan Cures Act; H.R. 5547 Maintaining Investments in New Innovation Act; S 3558 BIOSECURE Act; HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act); S Res 566 Cholesterol Education Month 2024; HR 7635 340B PATIENTS Act of 2024; H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act; H.R.8574 – 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 5376 Share the Savings With Seniors Act; S 3430 Mental Health, Lower Cost Drugs and Extenders Package; BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities; HR 8412 Clinical Trial Modernization Act…

Issues related to drug pricing reform; Changes to Public law 117-1769 Inflation Reduction Act; Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act; S. 113 Prescription Pricing for the People Act of 2023; S. 127 Pharmacy Benefit Manager Transparency Act; H.R. 485 Protecting Health Care for All Patients Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 2534 PROTECT 340B act of 2023; H.R. 3561 the PATIENT act; Issues related to cardiovascular disease awareness and treatment; Issues related to ESRD; Issues related to asthma and self-administered drug list; Issues related to reimbursement for biologics/biosimilars; Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program; H.R. 4818/ S2407 Treat and Reduce Obesity Act; S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act; Issues related to PAHPA reauthorization; Modernizing and Ensuring PBM Accountability Act (Finance Committee); S. 1542/HR 6283 DRUG Act; S. 652 SAFE Step Act; H.R. 3281 Protecting Patients Against PBM Abuses Act; H.R. 4822 Health Care Price Transparency Act of 2023; S. 1339 Pharmacy Benefit Manager Reform Act; H.R. 2679 Pharmacy Benefits Manager Accountability Act; H.R. 4507 Transparency in Coverage Act of 2023; S. 2474/HR 5376 Share the Savings with Seniors Act; S. 2456 Protecting Seniors from High Drug Costs Act; H.R. 4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program; H.R. 1352 Increasing Access to Biosimilars Act of 2023; H.R. 2880 Protecting Patients Against PBM Abuses Act; H.R. 5547 Maintaining Investments in New Innovation Act; H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC Act); H.R. 7635 340B PATIENTS Act of 2024; H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 8574 – 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 5376 Share the Savings With Seniors Act; S. 3430 Mental Health, Lower Cost Drugs and Extenders Package; HR 5539 Orphan Cures Act…

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; HR 3938 Build it in America Act…

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023; S. 113 Prescription Pricing for the People Act of 2023; S. 1250 Drug-price Transparency for Consumers Act; S. 127 Pharmacy Benefit Transparency Act; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop STALLING Act; S. 142 Preserve Access to Affordable Generics and Biosimilars; Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness/double patenting; S. 2140 Patent Eligibility Restoration Act of 2023; S. 2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act; S. 1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents; H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress; H.R. 3535 Advancing Americas Interests Act; H.R. 5475 Prohibiting Adversarial Patents Act of 2023; S. 3385/HR 8333 — BIOSECURE Act; BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities; Issues related to FDA/PTO coordination; S. 2780 Medication Affordability and Patent Integrity Act; Issues related to skinny labeling; S. 3583/HR 6986 To Address Patent Thickets; S. 1956 Invent It Here, Make It Here Act….

Now you know. Buffs win 41-27, to reach 7-2! Grin….

नमस्ते

Hinderaker: Dreaming, Of Things That Will Never Be…

~ condor ~ 1 Comment

Again, here on a Saturday night (perhaps because Dartmouth beat Princeton last night!), it seems John’s had more than a few high balls… so, he thinks that the Democratic Party brand is dead.

That’s just… silly. Although MAGA/GOP claims to be populist, it is in fact the party of billionaires.

Just watch what they do… not what they say.

There will be no lower class- or middle class-tax cut, but there will be vast tax cuts for billionaires.

By 2026 (if not before), Brown people will have seen the truths — behind these liars.

Again.

Onward.

Slightly Delayed, But It Seems Pfizer Decided Q3 2024 Was No Time To Lobby — With Congressional Campaigning In Full Swing…

~ condor ~ Leave a comment

We will have to see how Q4 2024 turns out, but Pfizer radically cut its lobby-spending in Q3, compared to last year — and even compared to its rough-peer-groups, in multinational pharma size. It dropped to about where the heavier spenders on the second tier of life science companies play — and spent only about a third of whay Amgen spent.

Me? I think the Manhattan HQ-ed company realized no one was “listening” — during the campaign rallies, nation-wide — to what big pharma had on its wish list. But here is what Pfizer’s much smaller outlay was spent on. We will do Merck tomorrow, and then Lilly, Amgen and the rest. [As ever, Amazon was about 4X, of these players.]

…VICP Reform and Excise Tax; Inflation Reduction Act (IRA); HR7174 – Ensuring Pathways to Innovative Cures (EPIC) Act; Medicare Price Setting; Part D Payer Utilization Management; Drug Shortages; S2916 – Prescription Information Modernization Act of 2023; Vaccines, Clinical Trials and Coverage; S2305 – Biosimilar Red Tape Elimination Act; Biosimilar Access and Interchangeability; HR 2666 – Medicaid Value Based Payments for Patients (MVP) Act; HR 4758 – Accelerating Kids Access to Care Act; HR 7384 – Rare Pediatric Disease Priority Review (PRV) Voucher; Trade-Related Aspects of Intellectual Property Rights; March-in Framework Guidance and Policies; S.79 – Interagency Patent Coordination and Improvement Act of 2023; S.142 – Preserve Access to Affordable Generics and Biosimilars Act; S.150 – Affordable Prescriptions for Patients Act of 2023; S.2780 – Medication Affordability and Patent Integrity Act; Digital: Data Flows and Digital Trade….

S723/HR1458 – Access to Prescription Digital Therapeutics Act; HR8816 – American Medical Innovation and Investment Act of 2024; PBM Transparency and Reform; S1542/HR6283 – Delinking Revenue from Unfair Gouging (DRUG) Act; HR2880 – Protecting Patients Against PBM Abuses Act; HR5378 – Lower Costs More Transparency Act; 340B Reform; HR8574 – 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act….

Comprehensive Corporate Tax Reform; Tax Cuts and Jobs Act (TCJA); VICP Reform and Excise Tax; VICP Transition; Comprehensive Federal Tax Reform….

International Supply Chain; HR4307/S2115 – Medical Supply Chain Resiliency Act….

Now you know, and given the tumult we’ve seen this week — it is likely that a hung Congress will mean not a lot of Tangerine’s agenda (whatever that might entain for pharma) will ever come to pass. Again — two years… or, four years… of inertia (most likely — without even “concepts” of a plan). Y I K E S.

नमस्ते

Speaking Of Gravity Assists: ESA’s Hera “Has Left The Station” — Onward, To Mars!

~ condor ~ Leave a comment

The amount of fuel saved (and thus weight dropped — greatly reduces the need to “lift” very heavy spacecraft — ones with large liquid ox fuel tanks), leads most deep space missions to now rely on one or more gravity assist “manoeuvres” (to adopt the French formulation of that term, as below), to get to the destination(s).

So it is, with ESA’s Hera mission to Didymos, an doublet asteroid system… “way out there“. [And a prior one of our items, on this mission.] Here’s the full story:

…Hera is on a two-year journey to the Didymos binary asteroid system, where it will analyse the results of humankind’s first asteroid deflection experiment.

The recent deep-space manoeuvre was carefully calculated to line Hera up for a gravity assist in March 2025 that will shorten the travel time to Didymos.

“We are very fortunate that Mars is in the right place at the right time to lend a hand to Hera,” says Pablo Muñoz from ESOC’s Mission Analysis team, who planned Hera’s journey.

“This enabled us to design a trajectory that uses the gravity of Mars to accelerate Hera towards Didymos, offering substantial fuel savings to the mission and allowing Hera to arrive at the asteroids months earlier than would otherwise be possible….”

Hera fired its three orbital control thrusters for 100 minutes, kicking off its first deep-space manoeuvre and changing its velocity by approximately 146 m/s. A second burn on 6 November lasted 13 minutes with the aim of providing an additional boost of around 20 m/s.

Together, these burns have put Hera on a trajectory that will enable a gravity assist at Mars in March 2025….

Onward. Now you know; smiling.

नमस्ते

In Which Hinderaker… Vastly Overestimates What Was Actually In Evidence On Tuesday… Y A W N.

~ condor ~ 2 Comments

But that sort of manic / depressive cycling has forever been… the bi-polar guy that is John Hinderaker [and Steve Hayward].

He’s in manic mode, tonight — preposterously believing that the fact that Kamala Harris was forced into running a 103 day campaign… means that the world has fundamentally fallen in love with “Whatever the Hell” Trump now claims he is.

John forgets how — from 2017-2021 — the world learned… that Tangerine actually does NONE of the things he promises, during his campaigns. And he was nearly the least popular ex-preznit the day he left office, in the last 175 years — because of that. As one paper put it, in January of 2021: “Last Trump Job Approval 34%; Average Is Record-Low 41%” [Nine years later, he still only has a “concept of a plan“, for improving health care. Damn. What a… putz.]

By 2026 (if not before) — his popularity will be in the very low 30% range, because he is a pure charlatan. [BTW, where are those promised IRS Forms 1040, from him — now over a decade, later?! And how exactly did Mexico pay to build even one mile of his stupid wall?]

Let’s just quickly run down some of what he’s (preposterously) promised to accomplish, by March of 2025, to that end:

(i) Gas at under $2/gallon

(i) 50% decrease in car insurance rates

(iii) Sub 3% interest rates

(iv) Substantially cheaper rents, nationwide

(v) End all taxes on tips

(vi) End all taxes on Social Security

(vii) End all taxes on overtime wages

(viii) End Ukraine War by end of January ’25 [Question: does he plan to just “gift” Ukraine — to Vlad?!]

(ix) End Gaza / Israel War by end of February ’25

(x) Substantially decrease federal income taxes for all families earning under $200,000 a year (about 85% of all Americans) by March ’25

(xi) Cut federal budget — with Elon — by $2 trillion — before Summer 2025…

(xii) And… one he never said aloud, at a rally — but one he’s (certainly) promised Elon Musk and Sheldon Adelman’s widow: cut taxes in half for all billionaires in the USA.

Of course, except for (xii), he will do none of these things. He won’t even “build a wall” this time. He may deport more brown people — by 2027 or so… but his approvals will (again!) plummet — when everyone sees that only billionaires got their tax breaks.

So yeh, Johnnie, you and chubby Stevie go ahead — and slobber all over those charts you’re making.

They are tomorrow’s bird-cage liners.

Out.

UPDATE: Rudy G. Continues To Flirt With Getting… Jailed In Manhattan.

~ condor ~ Leave a comment

Just so the Powerline boys can keep track of “all the best people“ Tangerine now proposes to have advise him, in his coming [mal-]Administration, we offer this morning’s minute order, from USDC Judge Liman in Manhattan, after Rudy’s ongoing foot-dragging, on his prior orders to turn over property (he no longer owns) — to pay two Georgia election workers some of the $148 million he owes them for defaming them:

…ORDER: This order memorializes the oral orders made at the hearing held on November 7, 2024, based on the dates provided by the parties:

(1) Defendant has until Monday, November 11, 2024 to amend his responses to the Information Subpoena to give full and complete answers under oath, and, inter alia, shall give a full and complete answer under oath to Question 13 of the Information Subpoena served to him on August 5, 2024, see Dkt. No. 70 3, 21.

(2) Plaintiff-Receivers have until Monday, November 11, 2024 to instruct Defendant, pursuant to Paragraph 4(f) of the Court’s turnover and receivership order of October 22, 2024 (the “Turnover Order”), see Dkt. No. 62, of the location to which all outstanding property listed on pp. 1718 of the Turnover Order shall be delivered by Defendant and/or his agents to the Receiver and the means by which it shall be delivered to the Receiver (including, but not limited to, the terms of appropriate insurance coverage).

(3) Defendant has until Friday, November 15, 2024 to comply with the Plaintiff-Receivers’ instructions and to deliver to the Plaintiff-Receivers all items of property identified in the Turnover Order, according to the Plaintiff-Receivers’ instructions.

(4) Defendant has until Thursday, November 14, 2024 to submit a motion to modify the Turnover Order to require the Plaintiff-Receivers to treat Defendant’s New York co-op property as his homestead pursuant to C.P.L.R. 5206. The Plaintiffs have until Monday, November 18, 2024 to respond, and Defendant then has until Thursday, November 21, 2024 to reply.

Any request for modification of this Order shall be filed only after the parties have met and conferred and no later than one business day before the operative deadline sought to be modified. The parties are warned that continued violation of the Turnover Order may result in contempt sanctions….

Signed by Judge Lewis J. Liman on 11/8/2024….

Hilarious. He’s… flat out of runway.